Clearance mechanisms are key to removing aggregates and maintaining metastability.

A designer version of the tau protein, developed by a team led by UT Southwestern Medical Center researchers, maintains its biological function while resisting aggregation, a pathological trait linked ...

Raghu R. Chivukula, MD, Ph.D., a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is ...

Protein-based therapeutics have transformed treatments for numerous diseases, yet their production remains highly complex and cost-intensive [1][2],[3][4]. Downstream processing (DSP), including ...

Neurodegenerative diseases, such as Alzheimer's disease and dementia, are medical conditions that entail the progressive loss of neurons and a decline in brain function. Past studies have found a link ...

A new large-scale study has mapped the first molecular events that drive the formation of harmful amyloid protein aggregates found in Alzheimer’s disease, pointing towards a new potential therapeutic ...

The accumulation of misfolded proteins in the brain is central to the progression of neurodegenerative diseases like Huntington's, Alzheimer's and Parkinson's. But to the human eye, proteins that are ...

The accumulation of misfolded proteins in the brain is central to the progression of neurodegenerative diseases like Huntington’s, Alzheimer’s and Parkinson’s. But to the human eye, proteins that are ...

In a recent study published in the journal Nature, a group of researchers investigated how aging alters neuronal protein degradation, aggregation, and transfer to microglia, with a focus on synaptic ...

CGSchNet, a fast machine-learned model, simulates proteins with high accuracy, enabling drug discovery and protein engineering for cancer treatment. Operating significantly faster than traditional all ...